YAP1 and neuroblastoma: Small molecules that inhibit TEAD auto-palmitoylation, a post-translational modification essential for TEAD activation and binding to YAP, pre-clinically show efficacy in NF2-mutated malignant mesothelioma and meningiomas or schwannomas, leading to a first in human phase 1 clinical trial in those tumor types, supporting the need to assess their efficacy in YAP-driven neuroblastoma [164,165,166].